Endocrinology, Diabetes & Metabolism (Sep 2023)

The LongitudinAl Nationwide stuDy on Management And Real‐world outComes of diabetes in India over 3 years (LANDMARC trial)

  • Ashok K. Das,
  • Sanjay Kalra,
  • Shashank Joshi,
  • Ambrish Mithal,
  • K. M. Prasanna Kumar,
  • A. G. Unnikrishnan,
  • Hemant Thacker,
  • Bipin Sethi,
  • Subhankar Chowdhury,
  • Amarnath Sugumaran,
  • Ashwini Satpathy,
  • Arvind Gadekar,
  • Shalini K. Menon,
  • Renuka Neogi,
  • Deepa Chodankar,
  • Chirag Trivedi,
  • S. K. Wangnoo,
  • A. H. Zargar,
  • Nadeem Rais,
  • LANDMARC study group

DOI
https://doi.org/10.1002/edm2.422
Journal volume & issue
Vol. 6, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract Introduction LANDMARC (CTRI/2017/05/008452), a prospective, observational real‐world study, evaluated the occurrence of diabetes complications, glycemic control and treatment patterns in people with type 2 diabetes mellitus (T2DM) from pan‐India regions over a period of 3 years. Methods Participants with T2DM (≥25 to ≤60 years old at diagnosis, diabetes duration ≥2 years at the time of enrollment, with/without glycemic control and on ≥2 antidiabetic therapies) were included. The proportion of participants with macrovascular and microvascular complications, glycemic control and time to treatment adaptation over 36 months were assessed. Results Of the 6234 participants enrolled, 5273 completed 3 years follow‐up. At the end of 3‐years, 205 (3.3%) and 1121 (18.0%) participants reported macrovascular and microvascular complications, respectively. Nonfatal myocardial infarction (40.0%) and neuropathy (82.0%) were the most common complications. At baseline and 3‐years, 25.1% (1119/4466) and 36.6% (1356/3700) of participants had HbA1c <7%, respectively. At 3‐years, population with macrovascular and microvascular complications had higher proportion of participants with uncontrolled glycemia (78.2% [79/101] and 70.3% [463/659], respectively) than those without complications (61.6% [1839/2985]). Over 3‐years, majority (67.7%–73.9%) of the participants were taking only OADs (biguanides [92.2%], sulfonylureas [77.2%] and DPP‐IV inhibitors [62.4%]). Addition of insulin was preferred in participants who were only on OADs at baseline, and insulin use gradually increased from 25.5% to 36.7% at the end of 3 years. Conclusion These 3‐year trends highlight the burden of uncontrolled glycemia and cumulative diabetes‐related complications, emphasizing the importance of optimizing diabetes management in India.

Keywords